Circulating tumor DNA: toward evolving the clinical paradigm of pancreatic ductal adenocarcinoma

Article Oncology

Survival of cancer survivors with a new pancreatic cancer diagnosis

Sandi L. Pruitt et al.

Summary: Pancreas cancer patients who have previously had another cancer have similar survival rates to those without previous cancer, suggesting that cancer survivors should be considered for inclusion in pancreas cancer clinical trials.

CANCER MEDICINE (2023)

添加到收藏夹

Article Oncology

Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer

James T. Topham et al.

Summary: This study aimed to explore the acquired resistance mechanisms in metastatic colorectal cancer patients after anti-epidermal growth factor receptor (EGFR) antibody treatment. The results indicated that multiple genes experienced increased mutation frequency, concurrent alterations, and copy gains in patients following anti-EGFR therapy. Furthermore, gene fusions were found to be associated with prior anti-EGFR therapy. The study also highlighted the prevalence of polyclonal resistance in patients with prior anti-EGFR treatment. This research provides valuable insights into the acquired resistance mechanisms of anti-EGFR therapy.

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Review Oncology

Circulating tumour DNA: a challenging innovation to develop precision onco-surgery in pancreatic adenocarcinoma

Daniel Pietrasz et al.

Summary: Pancreatic ductal adenocarcinoma is expected to become the third leading cause of cancer-related deaths. Liquid biopsy and circulating biomarkers show promise in improving its treatment. Circulating tumor DNA is the most studied liquid biopsy analyte, providing real-time insights into molecular profiles and individual characteristics of the tumor.

BRITISH JOURNAL OF CANCER (2022)

添加到收藏夹

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

添加到收藏夹

Article Oncology

Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements

Alison M. Schram et al.

Summary: NRG1 rearrangements are recurrent oncogenic drivers in solid tumors, and targeting HER2 and HER3 simultaneously with the bispecific antibody Zeno is an effective therapeutic strategy for NRG1 fusion-positive cancers, providing durable clinical responses for patients.

CANCER DISCOVERY (2022)

添加到收藏夹

Review Oncology

A Breakthrough Brought about by Targeting KRASG12C: Nonconformity Is Punished

Wenjuan Ning et al.

Summary: KRAS is the most common oncogene in human cancers, with G12C inhibitors providing a breakthrough by covalently targeting the G12C substitution and demonstrating potent clinical efficacy. However, challenges such as drug resistance must be addressed to maximize the efficacy of KRAS(G12C) inhibitor therapy. Combination treatments with other therapeutic agents and an understanding of compensatory signaling pathways are promising strategies to overcome these challenges.

CANCERS (2022)

添加到收藏夹

Article Oncology

Impact of the COVID-19 Pandemic on Management of Patients with Metastatic Pancreatic Ductal Adenocarcinoma in the United States

Ravi Paluri et al.

Summary: This study compared health care patterns and outcomes for patients diagnosed with metastatic pancreatic ductal adenocarcinoma (mPDAC) in 2019 and 2020 during the COVID-19 pandemic, finding that during the pandemic, patients were more likely to be initially diagnosed at advanced stages and experienced adversely affected survival outcomes.

ONCOLOGIST (2022)

添加到收藏夹

Article Medicine, General & Internal

Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer

Jeanne Tie et al.

Summary: This study found that using ctDNA results to guide treatment decisions for stage II colon cancer reduced the use of adjuvant chemotherapy without compromising recurrence-free survival.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Multidisciplinary Sciences

The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma

Daniel J. Renouf et al.

Summary: Combining immunotherapy with chemotherapy does not improve survival in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC), and can cause toxicity with elevated lymphocyte levels.

NATURE COMMUNICATIONS (2022)

添加到收藏夹

Article Oncology

Delving into Early-onset Pancreatic Ductal Adenocarcinoma: How Does Age Fit In?

Erica S. Tsang et al.

Summary: This study analyzed genomic and transcriptomic data from a large cohort of PDAC patient samples, revealing a distinctive pattern of biallelic CDKN2A mutation and increased expression of FOXC2 in EOPC tumors. The correlation between FOXC2 and EMT pathways represents novel molecular characteristics of EOPC.

CLINICAL CANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Cancer Statistics, 2021

Rebecca L. Siegel et al.

Summary: Every year, the American Cancer Society projects the numbers of new cancer cases and deaths in the United States, with the latest data showing a significant decline in lung cancer mortality, while prostate cancer mortality has plateaued and breast and colorectal cancer mortality have slowed. Improvements in treatment have accelerated progress against lung cancer, leading to a record drop in overall cancer mortality.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Molecular pro fi ling of ctDNA in pancreatic cancer: Opportunities and challenges for clinical application

L. Sivapalan et al.

Summary: PDAC is expected to become the second leading cause of cancer-related mortality in the next decade, with limited treatment options and poor long-term prognosis. Liquid biopsies, particularly ctDNA analyses, are increasingly being studied as a promising avenue for enhancing the characterization of PDAC tumor genomes, potentially leading to new therapeutic targets and improved treatment stratification. Challenges in terms of technical, analytical and biological aspects need to be addressed for the full realization of the potential of liquid biopsies in PDAC management.

PANCREATOLOGY (2021)

添加到收藏夹

Article Oncology

Circulating Tumor DNA-Based Testing and Actionable Findings in Patients with Advanced and Metastatic Pancreatic Adenocarcinoma

Gehan Botrus et al.

Summary: This study characterized the genomic alteration landscape of ctDNA in advanced PDAC patients, identifying therapeutically relevant alterations and providing a benchmark for further development in the field.

ONCOLOGIST (2021)

添加到收藏夹

Article Oncology

Interpreting Sequence Variation in PDAC-Predisposing Genes Using a Multi-Tier Annotation Approach Performed at the Gene, Patient, and Cohort Level

Michael T. Zimmermann et al.

Summary: The study investigated germline variation in pancreatic ductal adenocarcinoma (PDAC) predisposition genes, revealing mutations that affect patient survival and treatment response. Patients with metastatic PDAC carrying pathogenic variants showed improved survival, highlighting the potential for personalized medicine applications.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Clinical Utility of Circulating Tumor DNA in Advanced Rare Cancers

Hitomi Sumiyoshi Okuma et al.

Summary: Plasma NGS testing was conducted on 98 patients with rare cancers, showing that it can identify genetic alterations in a short timeframe and guide treatment decisions. In some cases, the results of plasma NGS testing were concordant with tissue NGS results, providing valuable information for the treatment of rare cancers.

FRONTIERS IN ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Clinical and cost outcomes following genomics-informed treatment for advanced cancers

Deirdre Weymann et al.

Summary: This study aimed to evaluate the impact of genomics-informed treatment on clinical and cost outcomes for cancer patients using the Difference-in-Difference method. The results showed a significant effect of genomics-informed treatment on time to treatment discontinuation and time to next treatment compared to standard care, but with increased treatment costs.

CANCER MEDICINE (2021)

添加到收藏夹

Article Oncology

Management of Patients with Pancreatic Ductal Adenocarcinoma in the Real-Life Setting: Lessons from the French National Hospital Database

Christelle de la Fouchardiere et al.

Summary: Pancreatic adenocarcinoma remains a significant public health challenge, with disparities and delays in diagnosis and access to care. A study in France found an inverse correlation between the expertise level of the healthcare facility and the likelihood of receiving specific treatment for PDAC. Further analysis is needed to identify medical and territorial factors impacting patient outcomes.

CANCERS (2021)

添加到收藏夹

Review Gastroenterology & Hepatology

Recent advances in precision medicine for pancreatic ductal adenocarcinoma

Hiromitsu Hayashi et al.

Summary: Pancreatic ductal adenocarcinoma (PDAC) is a major cause of cancer mortality globally, with chemoresistance posing a significant treatment challenge due to the heterogeneity of tumor cells and stromal cells. Precision medicine based on the genetics and molecular biology of PDAC may offer a promising alternative approach to overcome this heterogeneity and improve patient outcomes. Advances in genetic analysis have identified actionable gene mutations in PDAC, providing potential targets for more effective personalized treatment strategies.

ANNALS OF GASTROENTEROLOGICAL SURGERY (2021)

添加到收藏夹

Article Oncology

Clinical Implications of Pre- and Postoperative Circulating Tumor DNA in Patients with Resected Pancreatic Ductal Adenocarcinoma

Takuro Yamaguchi et al.

Summary: In patients with PDAC, the presence of preoperative ctDNA was significantly associated with poor OS, while postoperative ctDNA was not associated with poor survival. A positive change in ctDNA status did not affect patients' survival.

ANNALS OF SURGICAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial

Michael J. Pishvaian et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Circulating Cell-Free DNA-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic Cancer

Marta Toledano-Fonseca et al.

CANCERS (2020)

添加到收藏夹

Article Oncology

Circulating Tumor DNA as a Potential Marker to Detect Minimal Residual Disease and Predict Recurrence in Pancreatic Cancer

Jiahong Jiang et al.

FRONTIERS IN ONCOLOGY (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies

Yoshiaki Nakamura et al.

NATURE MEDICINE (2020)

添加到收藏夹

Article Medicine, General & Internal

Risk of Developing Pancreatic Cancer in Patients with Chronic Pancreatitis

Miroslav Vujasinovic et al.

JOURNAL OF CLINICAL MEDICINE (2020)

添加到收藏夹

Review Oncology

KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities

Claudio Luchini et al.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2020)

添加到收藏夹

Article Oncology

Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer

Vincent P. Groot et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Oncology

NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma

Martin R. Jones et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Oncology

Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood

Maryam A. L. Eissa et al.

CLINICAL EPIGENETICS (2019)

添加到收藏夹

Article Oncology

Circulating tumor DNA use in a community oncology practice

Erin D. Chamberlain et al.

TRANSLATIONAL CANCER RESEARCH (2019)

添加到收藏夹

Article Oncology

Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer

B. Lee et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

Talia Golan et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Oncology

Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion

E. M. O'Reilly et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Multidisciplinary Sciences

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

Jude Canon et al.

NATURE (2019)

添加到收藏夹

Article Oncology

KRAS Mutant Allele Fraction in Circulating Cell-Free DNA Correlates With Clinical Stage in Pancreatic Cancer Patients

Zhe-Ying Wang et al.

FRONTIERS IN ONCOLOGY (2019)

添加到收藏夹

Article Oncology

NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer

Christoph Heining et al.

CANCER DISCOVERY (2018)

添加到收藏夹

Article Oncology

Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer

S. Kruger et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Meeting Abstract Oncology

Analytical validation of a comprehensive 500-gene ctDNA panel designed for immuno-oncology and DNA damage research

Elena Helman et al.

CANCER RESEARCH (2018)

添加到收藏夹

Article Multidisciplinary Sciences

Utility of targeted deep sequencing for detecting circulating tumor DNA in pancreatic cancer patients

Gahee Park et al.

SCIENTIFIC REPORTS (2018)

添加到收藏夹

Article Oncology

Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial

Kyaw L. Aung et al.

CLINICAL CANCER RESEARCH (2018)

添加到收藏夹

Article Surgery

Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma

Vincent P. Groot et al.

ANNALS OF SURGERY (2018)

添加到收藏夹

Review Radiology, Nuclear Medicine & Medical Imaging

Imaging modalities in the diagnosis of pancreatic adenocarcinoma: A systematic review and meta- analysis of sensitivity, specificity and diagnostic accuracy

James Toft et al.

EUROPEAN JOURNAL OF RADIOLOGY (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers

Joshua D. Cohen et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)

添加到收藏夹

Article Oncology

Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer

Patricia Adamo et al.

ONCOTARGET (2017)

添加到收藏夹

Article Genetics & Heredity

The cost and cost trajectory of whole-genome analysis guiding treatment of patients with advanced cancers

Deirdre Weymann et al.

MOLECULAR GENETICS & GENOMIC MEDICINE (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Early changes in plasma DNA levels of mutant KRAS as a sensitive marker of response to chemotherapy in pancreatic cancer

Marzia Del Re et al.

SCIENTIFIC REPORTS (2017)

添加到收藏夹

Article Economics

Cost analysis of whole genome sequencing in German clinical practice

Marika Ploethner et al.

EUROPEAN JOURNAL OF HEALTH ECONOMICS (2017)

添加到收藏夹

Article Oncology

Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition

Nikolaos Ioanou et al.

INTERNATIONAL JOURNAL OF ONCOLOGY (2016)

添加到收藏夹

Review Oncology

Clinical applications of circulating tumor DNA and circulating tumor cells in pancreatic cancer

Francesca Riva et al.

MOLECULAR ONCOLOGY (2016)

添加到收藏夹

Article Oncology

KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control study

Florence Le Calvez-Kelm et al.

ONCOTARGET (2016)

添加到收藏夹

Article Oncology

Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer

Julie Earl et al.

BMC CANCER (2015)

添加到收藏夹

Article Oncology

Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer

Hideaki Kinugasa et al.

CANCER (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Whole genomes redefine the mutational landscape of pancreatic cancer

Nicola Waddell et al.

NATURE (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA

Richard B. Lanman et al.

PLOS ONE (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer

Erina Takai et al.

SCIENTIFIC REPORTS (2015)

添加到收藏夹

Article Cell Biology

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

Chetan Bettegowda et al.

SCIENCE TRANSLATIONAL MEDICINE (2014)

添加到收藏夹

Article Gastroenterology & Hepatology

Pancreatic ductal adenocarcinoma: Risk factors, screening, and early detection

Andrew E. Becker et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2014)

添加到收藏夹

Article Medicine, General & Internal

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Daniel D. Von Hoff et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

添加到收藏夹

Article Medicine, General & Internal

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Thierry Conroy et al.

NEW ENGLAND JOURNAL OF MEDICINE (2011)

添加到收藏夹

Article Biochemistry & Molecular Biology

Circulating mutant DNA to assess tumor dynamics

Frank Diehl et al.

NATURE MEDICINE (2008)

添加到收藏夹

Article Multidisciplinary Sciences

Detection and quantification of mutations in the plasma of patients with colorectal tumors

F Diehl et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)

添加到收藏夹

Circulating tumor DNA: toward evolving the clinical paradigm of pancreatic ductal adenocarcinoma

相关参考文献

导出引文

分享论文